Biovitrum and Symphogen enter into a collaboration around recombinant polyclonal antibodies
10 mai 2004 05h09 HE
|
Biovitrum
STOCKHOLM, Sweden, May 10, 2004 (PRIMEZONE) -- Biovitrum AB and The Danish biotech company Symphogen A/S have signed a fee-for-service agreement, which involves process development and production of...
Biovitrum licenses a project in metabolic diseases from Synaptic, a wholly owned subsidiary of Lundbeck
28 avr. 2004 05h03 HE
|
Biovitrum
STOCKHOLM, Sweden, April 28, 2004 (PRIMEZONE) -- Biovitrum AB has agreed with Synaptic Pharmaceutical Corporation to license a novel and competitive project within the field of metabolic diseases....
Biovitrum signs agreement to become sole supplier of Wyeth's Hemophilia drug ReFacto
26 janv. 2004 04h12 HE
|
Biovitrum
STOCKHOLM, Sweden, Jan. 26, 2004 (PRIMEZONE) -- Biovitrum has signed an agreement with Wyeth (NYSE: WYE) to be the sole supplier of its recombinant factor VIII drug ReFacto(R), for the treatment of...
Tripos and Biovitrum Announce Successful Chemistry Partnership Results and new Informatics Research Collaboration
08 déc. 2003 02h13 HE
|
Biovitrum
STOCKHOLM, Sweden and ST. LOUIS, Dec. 08, 2003 (PRIMEZONE) -- Tripos, Inc. (Nasdaq:TRPS) and the Swedish biotech company Biovitrum today announced positive results from the companies' discovery...
Biovitrum creates new business unit and secures multi-year agreement with Amgen
28 oct. 2003 05h34 HE
|
Biovitrum
STOCKHOLM, Sweden, Oct. 28, 2003 (PRIMEZONE) -- Biotechnology company Biovitrum, has established a new business unit, Biovitrum Biopharmaceuticals, with the purpose of strengthening its position as a...
Amgen and Biovitrum sign license agreement for innovative treatment of type 2 diabetes and other metabolic disorders
08 sept. 2003 09h07 HE
|
Biovitrum
STOCKHOLM, Sweden, Sept. 08, 2003 (PRIMEZONE) -- Amgen Inc. (Nasdaq:AMGN) and Biovitrum AB today announced that they have signed a multifaceted agreement under which Amgen receives exclusive rights...
Biovitrum and GlaxoSmithKline to Focus Efforts
22 mai 2003 05h53 HE
|
Biovitrum
STOCKHOLM, Sweden, May 22, 2003 (PRIMEZONE) -- Biovitrum AB today announced that Biovitrum and GlaxoSmithKline (Other OTC:GLAXF) have jointly decided to focus their efforts on the development of...
Biovitrum Initiates Clinical Phase IIb Study of Anti-Obesity Treatment
07 avr. 2003 04h04 HE
|
Biovitrum
STOCKHOLM, Sweden, April 7, 2003 (PRIMEZONE) -- Biovitrum today announced the start of a clinical Phase IIb study of the anti-obesity compound BVT.933 (GW876167), a 5-HT2C receptor agonist for the...
Biovitrum Initiates Phase II Study with its Diabetes Candidate Drug BVT.3498
25 mars 2003 04h06 HE
|
Biovitrum
STOCKHOLM, Sweden, March 25, 2003 (PRIMEZONE) -- Biovitrum today announced the initiation of a Phase II clinical trial of BVT.3498, its lead compound for type 2 diabetes. The primary end-point of the...
Biovitrum Signs Agreement with Lundbeck to Produce Protein Therapeutics
14 janv. 2003 04h08 HE
|
Biovitrum
STOCKHOLM, Sweden, Jan. 14, 2003 (PRIMEZONE) -- Biovitrum AB today announces a commission agreement with the Danish pharmaceutical company Lundbeck A/S for the production of a protein...